HR Execs on the Move

Bellus Health

www.bellushealth.com

 
BELLUS Health is a clinical stage biotechnology company developing novel therapeutics for the treatment of chronic cough and other chronic disorders triggered by hypersensitization.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Catherine Tittley
Senior Director of Human Resources Profile

Similar Companies

ProThera Biologics (Main)

ProThera Biologics, LLC (Main) is a East Providence, RI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Walter Payton Cancer Fund

Walter Payton Cancer Fund is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BioMx

BioMx is a South Amboy, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arbutus Biopharma

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV, we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). In addition, we are exploring oncology applications for our internal PD-L1 portfolio.

C2i Genomics

C2i Genomics is the first company to offer post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor`s DNA. Our liquid biopsy Whole Genome assay and cancer burden score will equip oncologists with vital timely information months to years before current monitoring methods are able to.